Health Trials

Open Label

3

Review clinical trials related to Open Label. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.

Participants needed: 15
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 24, 2026Locations: 1
Eligibility criteria

Histologically confirmed leiomyosarcoma (any site of origin). [+17]

Participants who are receiving any other investigational agents or have received... [+12]

Read more
Status: Not yet recruiting

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

A randomized, multicenter, open-label, active-controlled Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of multiple intravaginal doses of GenSci142 in patients with bacterial vaginosis (BV).

Participants needed: 30
Trial details
Phase: Phase 1Age: 18-50Biological sex: FemaleType: InterventionalSponsor: Changchun GeneScience Pharmaceutical Co., Ltd.Updated: Jun 23, 2026Locations: 7
Eligibility criteria

Women of childbearing age aged 18-50 years (inclusive of the cut-off values, as... [+7]

Those currently suffering from any acute infection of the urinary or reproductiv... [+20]

Read more
Status: Recruiting

A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma. The main question\[s\] it aims to answer are: * Is FX-909 safe and tolerable, as a monotherapy and in combination with Pembrolizumab * What is the right dose level for patients Participants will be asked to take FX-909 daily in tablet form, or FX-909 daily and Pembrolizumab every 3 weeks, and record any outcomes from taking the drug. Participants will also be asked to return for multiple site visits for various blood tests and to collect blood and tumor samples as well as have regular CT/MRI scans.

Participants needed: 120
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Flare Therapeutics Inc.Updated: Apr 20, 2026Locations: 12
Eligibility criteria

Able to understand and willing to sign an informed consent. [+5]

Female patients who are pregnant (confirmed with a positive pregnancy test) or b... [+70]

Read more